The Company is a biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions.


Updates from The Motley Fool

Latest updates on Affymax, Inc. from Fool.com.  The Fool has written over 100 articles on Affymax, Inc..
The Nasdaq's 5 Most Hated Stocks

Short-sellers certainly huffed and puffed with all of their might in May, but it wasn't meant to ...

5 of Last Week's Biggest Losers

There's never a shortage of losers in the stock market. Let's take a closer look at five of this ...

This Week in Biotech

With the  SPDR S&P Biotech Index  up 23% over the trailing-12-month period, it's evident that inv...

3 Stocks to Get on Your Watchlist

I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. W...

4 Stocks Making Moves

The following video is from Monday's Investor Beat, in which host Chris Hill and analysts Tim H...

What's Next for Affymax?

Affymax (NASDAQ: AFFY) received its first Food and Drug Administration approval last spring with...

Why Did My Stock Just Die?

So maybe we're going to go over the fiscal cliff after all. Talks between both sides in Washingto...

The Best of 2012: Affymax

It's the end of 2012, and that means it's time to take a look back at the year in retrospect. We'...

Why Affymax Shares Popped

Although we don't believe in timing the market or panicking over market movements, we do like to ...



Stock Performance

View Interactive AFFY Charts
Sponsored by

Key Data Points

Primary metrics and data points about Affymax, Inc..
Current Price: $0.07
Prev Close: $0.07
Open: $0.07
Bid: $0.00
Ask: $0.00
Day's Range: $0.07 - $0.08
52wk Range: $0.05 - $0.10
Volume: 9,751
Avg Vol 19,113
Market Cap: $3M
P/E (ttm): 0.88
EPS (ttm): $0.00
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Affymax, Inc..
CAPS Rating 2 out of 5
 
102 Outperform
36 Underperform
CAPS All Stars
 
8 Outperform
9 Underperform

How do you think Affymax, Inc. will perform against the market?



You pick for Affymax, Inc. is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


Business Summary

Industry, sector and description for Affymax, Inc..

The Company is a biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions.

  • Exchange: NASDAQOTH
  • Sector: Healthcare
  • Industry: Drug Makers